Legend Biotech

Legend Biotech Corp. is a holding company, which engages in the discovery and development of novel cell therapies for oncology and other indications. It operates through the North America and China geographical segments. The company was founded on May 27, 2015 and is headquartered in Somerset, NJ.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Legend Biotech surpasses Q2 sales targets, eyes market expansion

Legend Biotech's Q2 performance exceeded expectations with strong sales and positive study data.
The company's financial position is robust, with a healthy cash balance and plans for capacity expansion.
While facing challenges such as competitive pressures and operational optimizations, opportunities for growth exist.
Strategic initiatives focus on product quality, market expansion, and regulatory advancements for CARVYKTI.

Legend Biotech reports robust Q3 sales, eyes profitability targets

Legend Biotech's Q3 performance reflects strong sales driven by CARVYKTI, while maintaining a solid financial position with a focus on expansion.
The company faces challenges in achieving profitability targets and providing clarity on future sales projections.
Opportunities lie in pipeline advancements, collaboration partnerships, and innovative market expansion strategies.

Legend Biotech reports robust earnings, eyes expansion and regulatory milestones

Legend Biotech's strong earnings and cash balance provide stability and growth opportunities.
CARVYKTI's efficacy and convenience position it well, with plans for capacity expansion and partnerships.
Challenges include regulatory scrutiny and the need for clarity on future manufacturing scale-up.
Opportunities lie in extending manufacturing capacity, pipeline advancements, and profitability projections by 2026.

Legend Biotech reports robust Q1 performance and accelerates CAR-T expansion

Legend Biotech's Q1 2024 showcased strong performance with significant revenue growth and expansion plans to meet rising demand.
While facing challenges like sequential sales decrease and increased expenses, the company is leveraging strengths in production capacity and market diversification.
Opportunities lie in regulatory engagements for accelerated approvals, efficient market penetration strategies, and financial flexibility for future growth.
Overall, Legend Biotech's strategic focus on CAR-T therapies positions it well for continued success and innovation in the biopharmaceutical industry.

Legend Biotech excels in Q2, eyes FDA approvals and growth

Legend Biotech's Q2 2024 performance reflects strong sales growth, regulatory milestones, and promising clinical data, positioning the company for future success.
With a solid financial position, expanded production capacity, and ongoing research initiatives, Legend Biotech demonstrates resilience and strategic foresight in a competitive market landscape.
While facing challenges such as political risks and profitability targets, the company remains focused on growth opportunities and value creation for stakeholders.

Legend Biotech excels in Q3 with CARVYKTI growth and strategic advancements

Legend Biotech's Q3 performance reflects strong sales growth, regulatory milestones, and progress in clinical trials, underpinned by a robust balance sheet and strategic leadership appointments.
While challenges in outpatient treatment adoption and trial enrollment persist, the company's focus on innovation and operational excellence presents opportunities for future growth and market leadership.
Overall, Legend Biotech's solid financial standing, coupled with its expanding product portfolio and research capabilities, positions the company favorably for continued success and value creation for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

Legend Biotech Corporation Sponsored ADR (LEGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Legend Biotech Corporation Sponsored ADR (LEGN) Stock Jumps 14.2%: Will It Continue to Soar?

Legend Biotech (LEGN) reports $55 million as preliminary sales figures for its multiple myeloma therapy in third-quarter 2022. Shares rise 14.2% post the announcement.

Legend's (LEGN) Q3 Carvykti Preliminary Sales Top Expectations

The company presented news regarding early revenue figures for a multiple myeloma therapy it collaborated on.

Why Legend Biotech's Shares Jumped 14.2% On Tuesday

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Japan's Ministry of Health, Labour and Welfare (MHLW) has approved CARVYKTI™ for the treatment of adults with relapsed or refractory MM.

CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced it will host its in-person and virtual Research & Development Day on Monday, October 3, 2022 at 10:00 a.m. ET at Andaz 5th Avenue in New York City. Please click here to register for the event. The event will feature a comprehensive overview of our platforms

Legend Biotech to Host 2022 R&D Day on Monday, October 3, 2022

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today in conjunction with an announcement to be issued by Legend Biotech's majority shareholder, GenScript Biotech Corporation, pursuant to the rules of The Stock Exchange of Hong Kong Limited, announced preliminary, unaudited financial results for the six-months ended June 3

Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2022

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the appointment of three new directors to its Board: Mr. Tomas Heyman as Class I director of Legend Biotech, Dr. Fangliang “Frank” Zhang as Class II director of Legend Biotech, and Dr. Li Mao as Class III director of Legend Biotech. Mr. Heyman and Dr. Mao were

Legend Biotech Appoints Three New Directors and Elects New Chairman of the Board

Legend Biotech Corporation Sponsored ADR (LEGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Legend Biotech Corporation Sponsored ADR (LEGN) Soars 10.9%: Is Further Upside Left in the Stock?

Investors, on second glance, might think the company's stock offering is a good idea.

Why Legend Biotech's Shares Jumped 11.8% on Wednesday

SOMERSET, N.J.--(BUSINESS WIRE)--July 2022 Follow-On Pricing Announcement

Legend Biotech Corporation Announces Pricing of Public Offering

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that it intends to offer and sell $250 million of American Depositary Shares (“ADSs”), each representing two ordinary shares, in an underwritten public offering. All ADSs to be sold in the proposed offering will be offered by Legend Biotech. Legend Biotech al

Legend Biotech Corporation Announces Proposed Public Offering

BMO Capital Markets initiated coverage on Legend Biotech Corporation (NASDAQ: LEGN) with a price target of $77, and an Outperform rating. The analyst says the company's recently approved Carvykti for multiple myeloma is best-in-class late-line CAR T therapy.

Legend Biotech Shares Move Higher After Bullish BMO Pitch

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech announces 28-month follow-up data for CARTITUDE-1 and the latest on CARTITUDE 2 cohorts A and B at ASCO 2022 Annual Meeting.

Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtagene Autoleucel Across Lines of Therapy in Patients with Multiple Myeloma

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech announces U.S. FDA clearance of its IND application for solid tumor CAR-T, LB1908.

Legend Biotech Announces U.S. FDA Clearance of IND Application for Solid Tumor CAR-T, LB1908 for Relapsed or Refractory Gastric, Esophageal and Pancreatic Cancers

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today reported its first quarter 2022 unaudited financial results. “The year began with an exciting start as we received the company's first-ever U.S. FDA approval for CARVYKTI™,” said Ying Huang, Ph.D., CEO of Legend Biotech. “This is the first of many cell therapies we hope

Legend Biotech Reports First Quarter 2022 Financial Results and Recent Highlights

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that it will host an investor event during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Taking place on Sunday, June 5 at 6pm Central Time, the meeting will feature Dr. Sundar Jagannath, Professor of Medicine, Hematology and Medical Onc

Legend Biotech to Host Investors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech announced that CARVYKTI has been granted conditional marketing authorization by the European Commission.

CARVYKTI® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech announced that eight company-sponsored abstracts were accepted at ASCO and EHA 2022.

Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma With Updated Data From BCMA CAR-T Studies at 2022 ASCO and EHA

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the promotion of Lori Macomber, CPA, to Chief Financial Officer (CFO), effective immediately. Ms. Macomber assumes the role from Dr. Ying Huang, who has been both CFO and Chief Executive Officer (CEO) since September 2020. Dr. Huang will continue to serve as CE

Legend Biotech Appoints Lori Macomber as Chief Financial Officer

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Achieves Milestone

Legend Biotech Achieves Milestone Under Collaboration Agreement with Janssen Biotech, Inc. for BCMA CAR-T

Immunocore Holdings

With trials aimed at increasing addressable markets in the coming years, Legend and Immunocore could reward investors.

2 Biotechs With Recent FDA Approvals to Hold for the Next Decade

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Announces Appointment of Global Head of Research and Early Development, Guowei Fang, Ph.D.

Legend Biotech Announces Appointment of Global Head of Research and Early Development

Johnson & Johnson

The European Medicines Agency's CHMP recommended conditional approval of Janssen, a unit of Johnson & Johnson (NYSE: JNJ), and its partner Legend Biotech Corporation's (NASDAQ: LEGN) CAR-T therapy to treat multiple myeloma. The drug, Carvykti (.

EMA's CHMP Clears Janssen, Legend's Multiple Myeloma CAR-T Therapy

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended Janssen Pharmaceutica NV's marketing authorization of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed an

CARVYKTI® (ciltacabtagene autoleucel) Receives Positive CHMP Opinion for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, was named Newcomer of the Year at the tenth annual Foreign Investment Trophy ceremony hosted by Flanders Investment & Trade (FIT). Flanders Investment and Trade is a Flemish government organization that facilitates investment projects in Flanders, a northern region of Belg

News for Legend Biotech Stock (LEGN)